Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer [0.03%]
利用吉西他滨代谢的潜力：迈向个性化医学治疗胰腺癌的第一步
Muhammad Wasif Saif,Yoomi Lee,Richard Kim
Muhammad Wasif Saif
Pancreatic cancer is a lethal malignancy with a 5-year survival rate of only 6%. Surgical resection remains the only cure, yet even after resection the 5-year survival is only 20% due to a high recurrence rate. Thus, a high proportion of pa...
Overcoming docetaxel resistance in prostate cancer: a perspective review [0.03%]
克服多西他赛耐药的前列腺癌治疗：综述透视
Clara Hwang
Clara Hwang
The treatment of metastatic castrate-resistant prostate cancer has been historically challenging, with few therapeutic successes. Docetaxel was the first cytotoxic therapy associated with a survival benefit in castrate-resistant prostate ca...
Older patients with breast cancer: is there bias in the treatment they receive? [0.03%]
老年乳腺癌患者接受治疗的情况是否存在偏见？
Christos Markopoulos,Willemien van de Water
Christos Markopoulos
Breast cancer is the most frequent malignant tumor in women worldwide and as breast cancer incidence increases with increasing age, over 40% of new cases are diagnosed in women older than 65 years of age. However, older patients are not tre...
Antiangiogenesis therapy in the treatment of metastatic colorectal cancer [0.03%]
抗血管生成疗法在转移性结直肠癌治疗中的应用
Axel Grothey,Carmen Allegra
Axel Grothey
The process of new blood vessel formation, or angiogenesis, has become an important target for therapeutic intervention in many cancers, including metastatic colorectal cancer (mCRC). The growth and metastasis of primary tumors is dependent...
Unusual suspects: pulmonary opportunistic infections masquerading as tumor metastasis in a patient with adrenocorticotropic hormone-producing pancreatic neuroendocrine cancer [0.03%]
可疑的罪犯：促肾上腺皮质激素产生的胰神经内分泌癌患者的伪装成肿瘤转移的机会性肺感染
Rajasree P Chowdry,Chandar Bhimani,Maria A Delgado et al.
Rajasree P Chowdry et al.
Pancreatic neuroendocrine tumors (p-NETs) are a rare group of neoplasms but with increasing incidence. The atypical complications that arise in the setting of functional endocrine tumors are underreported and therefore have not received suf...
A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre [0.03%]
一项关于生物类似物粒细胞集落刺激因子作为化疗引起的中性粒细胞减少症预防药物的非干预性研究
Karl Verpoort,Thomas M Möhler
Karl Verpoort
Objectives: Prophylaxis with granulocyte colony-stimulating factor (G-CSF) reduces the severity of chemotherapy-induced neutropenia. Biosimilar G-CSF is now approved for use, based on comparable efficacy, safety and quali...
Overcoming the stromal barrier: technologies to optimize drug delivery in pancreatic cancer [0.03%]
克服间质屏障：优化胰腺癌药物递送技术
Anastasios Dimou,Konstantinos N Syrigos,Muhammad Wasif Saif
Anastasios Dimou
Pancreatic cancer has historically proven resistant to anticancer agents. On the one hand, drugs might be more efficient if higher levels could be achieved at the tumor site rather than the normal tissues. On the other hand, the thick strom...
Current and emerging strategies for the management of imatinib-refractory advanced gastrointestinal stromal tumors [0.03%]
伊马替尼耐药胃肠道间质瘤的治疗策略
Damien Kee,John R Zalcberg
Damien Kee
Since its approval by the US Food and Drug Administration in February 2002, the tyrosine kinase inhibitor, imatinib, has become the standard of care for patients with metastatic or unresectable KIT-positive gastrointestinal stromal tumors (...
Therapeutic options in older patients with metastatic non-small cell lung cancer [0.03%]
老年晚期非小细胞肺癌患者的治疗选择
Elisabeth Quoix
Elisabeth Quoix
The increase in life expectancy, with its concomitant increase in the risk of cancer, has led to an increased incidence of lung cancer in older people. The median age at diagnosis of lung cancer is between 63 and 70 years. For a long time, ...
The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies [0.03%]
曲妥珠单抗-美坦辛偶联物治疗人类表皮生长因子受体2阳性的转移性乳腺癌的潜力：最新的证据和正在进行的研究
Sara A Hurvitz,Reva Kakkar
Sara A Hurvitz
The treatment of breast cancer that is driven by amplification and overexpression of human epidermal growth factor receptor 2 (HER2) has been drastically improved by the development of HER2-targeted therapies including trastuzumab and lapat...